Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + Chemo in Resectable NSCLC
NCT07129161Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07129161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129161.